|
|
|
PerkinElmer acquires SYM-BIO LifEScience with 435 million
|
| 2009-12-18 |
PerkinElmer, Inc. announced it has completed the acquisition of Shanghai-based SYM-BIO LifEScience, a provider of diagnostics instruments and related reagents, in a cash transaction equivalent to $ 63.7 million (RMB 435 million). The acquisition is expected to have no material impact on PerkinElmer's earnings per share for 2009 and be slightly accretive in 2010.
Ann-Christine Sundell, president, genetic screening, PerkinElmer said, “PerkinElmer and SYM-BIO LifEScience are very pleased to have the opportunity to introduce new products to advance the health of mothers and children in China, as well as assist in reducing the threat of major infectious diseases among at-risk patient populations. The acquisition strongly positions PerkinElmer in the fast-growing diagnostics market in China and expands our access to the market, as well as our offerings portfolio."
According to Zhang Sheng, president of SYM-BIO LifEScience, "The acquisition provides an unmatched opportunity for advanced products from SYM-BIO to be introduced to global markets. PerkinElmer also brings key technologies and expertise into the China market."
Source: PerkinElmer web site |
|
|
| 【打印】【关闭】 |
| |
|
|
|
| | |
|